Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

Obesity is in the news because of a new weight-loss drug in the form of a pill that can be taken any time of day, with or ...

Illumina & Ovation.io launch first-of-kind GLP-1 dataset to accelerate new therapy development: San Diego Saturday, May 3, 2025, 11:00 Hrs [IST] Illumina, Inc., and Ovation.io, In ...

A recent study presented at the 2025 International Society for Heart and Lung Transplantation (ISHLT) annual meeting suggests ...

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

Combined use of SGLT2 inhibitors and GLP-1 receptor agonists also significantly increased the risk for falls. (HealthDay News) — Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent ...

More dermatology patients are taking the popular drugs, but little is known about the biology of “Ozempic face” or how best ...

Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...

Newly identified neurons process multiple food cues to determine when an animal should stop eating, offering new clues into ...

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

Yet the disparities by sex, race/ethnicity, and location pale in comparison to a striking overall lack of adoption.

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...